Search

Abstract: Significant progress has been made over the past 50 years in the control of schistosomiasis japonica in China. However, recent data suggest that the disease is re-emerging. By the end of 2003, Schistosoma japonicum was still endemic in 110 counties in seven provinces in the southern part of China where the long-term reduction of the disease has been replaced by an increase in the number of people infected and areas infested by the intermediate host snail, i.e. Oncomelania hupensis. Explanations are multifactorial, including the construction of the Three Gorges dam, major flooding events, recovery of the Dongting Lake and the possible impact of climate change. An efficacious vaccine against S. japonicum would represent a significant addition to the current arsenal of control tools, particularly in the framework of an integrated control approach. The vaccine could be targeted either towards the prevention of infection or towards the reduction of parasite fecundity. Although progress in this field has been relatively slow, encouraging results have been obtained in recent years using defined native and recombinantly derived S. japonicum antigens. These findings suggest that development of a safe and efficacious vaccine is feasible. This paper reviews the progress in the development of a vaccine against S. japonicum in China, and includes also data from foreign researchers who are engaged in collaborative work with Chinese scientists. [Copyright &y& Elsevier]

BACKGROUND This study aimed to use gas chromatography-mass spectrometry (GC-MS) to identify the chemical constituents of volatile oil extracted by steam distillation from Cichorium glandulosum Boiss et Huet (CG), a traditional Uyghur medicine, and to investigate its effects on carbon tetrachloride (CCl₄)-induced hepatic fibrosis in rats. MATERIAL AND METHODS Sprague-Dawley rats (n=60) included six groups: the control group (n=10), untreated model group (n=10), the volatile oil of CG high-dose group (0.15 ml/kg) (n=10), the volatile oil of CG medium-dose group (0.10 ml/kg) (N=10), the volatile oil of CG low-dose group (0.05 ml/kg) (n=10), and the silybin-treated group (0.20 ml/kg) (n=10). Rats given the essential oil extract of CG by intragastric administration, and then subcutaneously injected with a solution of CCl₄ in olive oil to create the rat model of hepatic fibrosis. Serum samples were analyzed for markers of liver function, including aspartate transaminase (AST), alanine transaminase (ALT), malondialdehyde (MDA), hydroxyproline (Hyp), γ-glutamyl transpeptidase (γ-GT), lactate dehydrogenase (LDH), alkaline phosphatase (ALP), and albumin (Alb). Histology and immunohistochemistry were performed on rat liver tissue. RESULTS Thirty-eight compounds were identified from the volatile oil of CG (total, 98.058%), with terpenoids, including citronellol, being the most abundant. In the animal model of liver fibrosis, all doses of volatile oil of CG significantly reduced the serum levels of AST, ALT, MDA, Hyp, γ-GT, LDH, ALP, and Alb. CONCLUSIONS GC-MS identified the components of the volatile oil of CG, which included citronellol. Treatment with volatile oil of CG reduced liver fibrosis in a rat model.

Type 1 diabetes mellitus is heterogeneous in many facets. The patients suffered from type 1 diabetes present several levels of islet function as well as variable number and type of islet-specific autoantibodies. This study was to investigate prevalence and heterogeneity of the islet autoantibodies and clinical phenotypes of type 1 diabetes mellitus; and also discussed the process of islet failure and its risk factors in Chinese type 1 diabetic patients. A total of 1,291 type 1 diabetic patients were enrolled in this study. Demographic information was collected. Laboratory tests including mixed-meal tolerance test, human leukocyte antigen alleles, hemoglobinA1c, lipids, thyroid function and islet autoantibodies were conducted. The frequency of islet-specific autoantibody in newly diagnosed T1DM patients (duration shorter than half year) was 73% in East China. According to binary logistic regressions, autoantibody positivity, longer duration and lower Body Mass Index were the risk factors of islet failure. As the disease developed, autoantibodies against glutamic acid decarboxylase declined as well as the other two autoantibodies against zinc transporter 8 and islet antigen 2. The decrease of autoantibodies was positively correlated with aggressive beta cell destruction. Autoantibodies can facilitate the identification of classic T1DM from other subtypes and predict the progression of islet failure. As there were obvious heterogeneity in autoantibodies and clinical manifestation in different phenotypes of the disease, we should take more factors into consideration when identifying type 1 diabetes mellitus.

In order to evaluate immunogenicity and protective efficacy of LytA from Streptococcus pneumoniae, we subcloned the full-length lytA-encoded autolysin (LytA) from 5 major pathogenic serotype isolates in China and obtained purified rLytA. Bioinformatics analysis showed that sequences of LytA were highly conserved in all strains we used in this work, and western blot analysis demonstrated that rLytAs from heterogeneous serotypes were cross-recognized by serum of mice infected with 23F strain SH137. Mice were intranasally immunized with purified rLytA, and serum anti-rLytA IgG, IgA and secretory IgA were elicited. More importantly, rLytA intranasal-immunized mice showed a significantly higher survival rate and lower bacterial carriage in response to infection by Streptococcus pneumoniae. The fact that mice immunized with rLytA from strain SH137 also had a higher survival rate after intraperitoneal injection of other four serotype strains of living S. pneumoniae suggested that it possessed cross-protection effect. Our study revealed that intranasal immunization with rLytA may protect mice against mucosal and systemic pneumococcal infection; hence, it was an attractive vaccine candidate.